Tumor necrosis factor, but not neutrophils, alters the metabolic profile in acute experimental arthritis

• Autor(a) principal: Marina Chaves de Oliveira
• Data de Publicação: 2016
• Outros Autores: Luciana Padua Tavares, Juliana Priscila Vago da Silva, Nathália Vieira Batista, Celso Martins Queiroz Junior, Angelica Thomaz Vieira, Gustavo Batista de Menezes, Lirlândia Pires de Sousa, Fons Van De Loo, Mauro Martins Teixeira, Flávio Almeida Amaral, Adaliene Versiani Matos Ferreira
• Tipo de documento: Artigo
• Idioma: por
• Título da fonte: Repositório Institucional da UFMG
• Texto Completo: http://dx.doi.org/10.1371/journal.pone.0146403; http://hdl.handle.net/1843/53841; https://orcid.org/0000-0002-7423-9802; https://orcid.org/0000-0002-5319-0210; https://orcid.org/0000-0001-8188-3738; https://orcid.org/0000-0002-7884-7709; https://orcid.org/0000-0002-4556-7671; https://orcid.org/0000-0002-1042-9762; https://orcid.org/0000-0002-5851-099X; https://orcid.org/0000-0002-6944-3008; https://orcid.org/0000-0002-1695-0612; https://orcid.org/0000-0003-2256-8652
• topic: Tumor Necrosis Factors; Arthritis; Neutrophils; Fatores de Necrose Tumoral; Artrite; Neutrófilos

Metabolic alterations are associated with arthritis apart from obesity. However, it is still unclear which is the underlying process behind these metabolic changes. Here, we investigate the role of tumor necrosis factor (TNF) in this process in an acute model of antigen-induced arthritis (AIA). Immunized male BALB/c mice received an intra-articular injection of PBS (control) or methylated bovine serum albumin (mBSA) into their knees, and were also pre-treated with different drugs: Etanercept, an anti-TNF drug, DF2156A, a CXCR1/2 receptor antagonist, or a monoclonal antibody RB6-8C5 to deplete neutrophils. Local challenge with mBSA evoked an acute neutrophil influx into the knee joint, and enhanced the joint nociception, along with a transient systemic metabolic alteration (higher levels of glucose and lipids, and altered adipocytokines). Pre-treatment with the conventional biological Etanercept, an inhibitor of TNF action, ameliorated the nociception and the acute joint inflammation dominated by neutrophils, and markedly improved many of the altered systemic metabolites (glucose and lipids), adipocytokines and PTX3. However, the lessening of metabolic changes was not due to diminished accumulation of neutrophils in the joint by Etanercept. Reduction of neutrophil recruitment by pre-treating AIA mice with DF2156A, or even the depletion of these cells by using RB6-8C5 reduced all of the inflammatory parameters and hypernociception developed after AIA challenge, but could not prevent the metabolic changes. Therefore, the induction of joint inflammation provoked acute metabolic alterations which were involved with TNF. We suggest that the role of TNF in arthritis-associated metabolic changes is not due to local neutrophils, which are the major cells present in this model, but rather due to cytokines.